138 related articles for article (PubMed ID: 36941661)
1. Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer.
Son JH; Dong SR; Kim J; Kim J; Kong TW; Chang SJ
BMC Surg; 2023 Mar; 23(1):60. PubMed ID: 36941661
[TBL] [Abstract][Full Text] [Related]
2. Cholecystectomy as Part of Cytoreductive Surgery for Advanced Ovarian Cancer: Perioperative Outcomes.
Liakou CG; Akrivos N; Kumar B; Duncan TJ; Turnbull HL; Nieto JJ; Burbos N
Anticancer Res; 2020 Apr; 40(4):2331-2336. PubMed ID: 32234934
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
Zou RY; Yuan L; Chen M; Yao LQ
Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
[No Abstract] [Full Text] [Related]
6. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
7. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
[TBL] [Abstract][Full Text] [Related]
8. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
9. Complete tumor resection and demonstration of detailed anatomy of the porta hepatis in a patient with recurrent epithelial ovarian cancer.
Taskiran C; Vatansever D; Misirlioglu S; Giray B; Kumcular T; Arvas M; Erkan M
Int J Gynecol Cancer; 2021 Jan; 31(1):148-149. PubMed ID: 33303569
[No Abstract] [Full Text] [Related]
10. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
11. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
12. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer.
Song YJ; Lim MC; Kang S; Seo SS; Kim SH; Han SS; Park SY
Gynecol Oncol; 2011 May; 121(2):253-7. PubMed ID: 21277009
[TBL] [Abstract][Full Text] [Related]
13. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
[TBL] [Abstract][Full Text] [Related]
14. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
Gil-Moreno A; Alonso-Alconada L; Díaz-Feijoo B; Domingo S; Vilar A; Hernández A; Gilabert J; Llueca A; Torné A; de Santiago J; Carbonell-Socias M; Lago V; Arias E; Sampayo V; Siegrist J; Chipirliu A; Sánchez-Iglesias JL; Pérez-Benavente A; Padilla-Iserte P; Santacana M; Matias-Guiu X; Abal M; Lopez-Lopez R
Gynecol Oncol; 2021 Jun; 161(3):681-686. PubMed ID: 33795131
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
16. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
[TBL] [Abstract][Full Text] [Related]
18. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
[TBL] [Abstract][Full Text] [Related]
19. Porta hepatis debulking procedures as part of primary cytoreductive surgery for advanced ovarian cancer.
Son JH; Chang SJ; Ryu HS
Gynecol Oncol; 2017 Sep; 146(3):672-673. PubMed ID: 28688522
[No Abstract] [Full Text] [Related]
20. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
Bailey CD; Previs R; Fellman BM; Zaid T; Huang M; Brown A; Enbaya A; Balakrishnan N; Broaddus RR; Bodurka DC; Soliman P; Fleming ND; Nick A; Sood AK; Westin SN
Int J Gynecol Cancer; 2021 Feb; 31(2):232-237. PubMed ID: 33122243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]